The dilemma of a rising prostate-specific antigen level after local therapy: what are our options?
Publication/Presentation Date
6-1-2013
Abstract
Prostate cancer is the most common solid tumor diagnosed in men in the United States and Western Europe. Primary treatment with radiation or surgery is largely successful at controlling localized disease. However, a significant number (up to one third of men) may develop biochemical recurrence (BR), defined as a rise in serum prostate-specific antigen (PSA) level. A general presumption is that BR will lead to overt progression in patients over subsequent years. There are a number of factors that a physician must consider when counseling and recommending treatment to a patient with a rising PSA. These include the following (1) various PSA-based definitions of BR; (2) source of PSA (ie, local or distant disease, residual benign prostate); (3) available modalities to treat the disease with the least morbidity; and (4) timing of therapy. In this article we review the current and future factors that clinicians should consider in the diagnosis and treatment of recurrent prostate cancer.
Volume
40
Issue
3
First Page
322
Last Page
336
ISSN
1532-8708
Published In/Presented At
Zaorsky, N. G., Raj, G. V., Trabulsi, E. J., Lin, J., & Den, R. B. (2013). The dilemma of a rising prostate-specific antigen level after local therapy: what are our options?. Seminars in oncology, 40(3), 322–336. https://doi.org/10.1053/j.seminoncol.2013.04.011
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
23806497
Department(s)
Administration and Leadership
Document Type
Article